Alastair Greystoke
About
Alastair Greystoke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Alastair Greystoke has authored 144 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 75 papers in Pulmonary and Respiratory Medicine and 31 papers in Cancer Research. Recurrent topics in Alastair Greystoke's work include Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (21 papers) and Cancer Genomics and Diagnostics (20 papers). Alastair Greystoke is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (21 papers) and Cancer Genomics and Diagnostics (20 papers). Alastair Greystoke collaborates with scholars based in United Kingdom, United States and Spain. Alastair Greystoke's co-authors include Caroline Dive, Malcolm Ranson, Fiona Blackhall, Andrew Hughes, Matthew Krebs, Tim Ward, Lee Lancashire, Lynsey Priest, Robert Szczepaniak‐Sloane and Jianmei Hou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Alastair Greystoke
125 papers receiving 3.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Alastair Greystoke United Kingdom | 28 | 2.3k | 1.4k | 1.3k | 1.3k | 349 | 144 | 3.8k | ||
| Sofia Agelaki Greece | 40 | 3.6k 1.6× | 1.9k 1.4× | 1.5k 1.1× | 1.4k 1.1× | 357 1.0× | 216 | 5.0k | ||
| Tim Ward United Kingdom | 26 | 2.4k 1.0× | 1.5k 1.1× | 1.0k 0.8× | 1000 0.8× | 573 1.6× | 40 | 3.5k | ||
| Nashat Gabrail United States | 26 | 2.3k 1.0× | 1.1k 0.8× | 788 0.6× | 1.6k 1.3× | 388 1.1× | 154 | 4.4k | ||
| Mario Giuliano Italy | 34 | 2.4k 1.1× | 1.4k 1.0× | 1.2k 0.9× | 1.0k 0.8× | 189 0.5× | 109 | 3.8k | ||
| Daniel S.W. Tan Singapore | 34 | 1.8k 0.8× | 965 0.7× | 1.9k 1.4× | 1.3k 1.1× | 197 0.6× | 159 | 4.1k | ||
| Xiaoxiang Guan China | 38 | 2.0k 0.9× | 1.6k 1.2× | 910 0.7× | 2.5k 2.0× | 260 0.7× | 173 | 4.7k | ||
| Marzia Del Re Italy | 34 | 1.6k 0.7× | 1.3k 0.9× | 1.6k 1.2× | 1.5k 1.2× | 178 0.5× | 167 | 3.9k | ||
| Dimitris Mavroudis Greece | 43 | 3.9k 1.7× | 2.4k 1.7× | 1.5k 1.1× | 1.6k 1.3× | 352 1.0× | 107 | 5.2k | ||
| William Jacot France | 34 | 2.7k 1.2× | 1.2k 0.9× | 1.4k 1.0× | 1.1k 0.8× | 147 0.4× | 224 | 4.2k | ||
| Yang Lü United States | 35 | 1.9k 0.8× | 906 0.7× | 971 0.7× | 1.9k 1.5× | 220 0.6× | 171 | 4.5k |
Countries citing papers authored by Alastair Greystoke
Since
Specialization
Citations
This map shows the geographic impact of Alastair Greystoke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alastair Greystoke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alastair Greystoke more than expected).
Fields of papers citing papers by Alastair Greystoke
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alastair Greystoke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alastair Greystoke. The network helps show where Alastair Greystoke may publish in the future.
Co-authorship network of co-authors of Alastair Greystoke
This figure shows the co-authorship network connecting the top 25 collaborators of Alastair Greystoke. A scholar is included among the top collaborators of Alastair Greystoke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alastair Greystoke. Alastair Greystoke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Liu, Jia, Anna Minchom, Alastair Greystoke, et al.. (2025). Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 43(26). 2918–2929.
2.
Chouaïd, C., L. Bosquet, Craig Knott, et al.. (2025). Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 203. 108548–108548.
3.
Greystoke, Alastair, et al.. (2024). Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study. Cancer Epidemiology Biomarkers & Prevention. 33(10). 1298–1310.
4.
Crowe, Lisa, Morven C. Brown, Jan Lecouturier, et al.. (2024). “Oh when's your treatment ending?” “Never!” The unmet needs of cancer patients treated with immunological, biological and precision therapies: A qualitative interview study. European Journal of Oncology Nursing. 73. 102696–102696.
5.
Fontana, Emily, Meredith McKean, Raid Aljumaily, et al.. (2024). 647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study. Annals of Oncology. 35. S511–S512.
6.
Liu, Jia, Anna Minchom, Alastair Greystoke, et al.. (2024). Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.. Journal of Clinical Oncology. 42(16_suppl). 3014–3014.
7.
Lee, Siow Ming, Madeleine Hewish, Samreen Ahmed, et al.. (2024). Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. European Journal of Cancer. 215. 115162–115162.
8.
Hochmair, Maximilian J., Michael Schenker, Manuel Cobo, et al.. (2024). Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. Journal of Thoracic Oncology. 20(2). 203–218.
9.
Billingham, Lucinda, Theodor Framke, Alastair Greystoke, et al.. (2023). Histology independent drug development – Is this the future for cancer drugs?. Cancer Treatment Reviews. 123. 102674–102674.
10.
Crowe, Lisa, Morven C. Brown, Alastair Greystoke, et al.. (2023). Assessing the unmet needs of patients with advanced cancer treated by biological and precision therapies: protocol for TARGET, a mixed methods study. BMJ Open. 13(5). e066229–e066229.
11.
Messina, Carlo, Emilio Francesco Giunta, Alessio Signori, et al.. (2023). Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. European Urology Oncology. 7(2). 179–188.
12.
Ghiringhelli, François, Enriqueta Felip, Alona Zer, et al.. (2023). 1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study. Annals of Oncology. 34. S819–S820.
13.
Middleton, Gary, Lynley V. Marshall, Lucinda Billingham, et al.. (2023). 716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers. Annals of Oncology. 34. S494–S495.
14.
Liu, Jia, Anna Minchom, Alastair Greystoke, et al.. (2023). Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours. Molecular Cancer Therapeutics. 22(12_Supplement). B039–B039.
15.
Dewhurst, Felicity, et al.. (2023). Personalised Assessment and Rapid Intervention in Frail Patients With Lung Cancer: The Impact of an Outpatient Occupational Therapy Service. Clinical Lung Cancer. 24(5). e164–e171.
16.
Walker, Katrina, Samantha Hinsley, Anthony J. Chalmers, et al.. (2022). Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology. 6(6). e2200133–e2200133.
17.
Harvie, Michelle, Mary Pegington, Sacha J. Howell, et al.. (2021). Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British Journal of Cancer. 126(8). 1157–1167.
18.
Middleton, Gary, Sanjay Popat, Yvonne Summers, et al.. (2019). PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S7–S7.
19.
Basu, Bristi, Emma Dean, M. Puglisi, et al.. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research. 21(15). 3412–3419.
20.
Greystoke, Alastair, Kim Linton, Tim Illidge, et al.. (2008). Changes in serological biomarkers (BM) of cell death during chemotherapy (CT) in patients with lymphoma. Annals of Oncology. 19. 169–169.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sofia Agelaki Breakdown of academic impact, for papers by Tim Ward Breakdown of academic impact, for papers by Nashat Gabrail Breakdown of academic impact, for papers by Mario Giuliano Breakdown of academic impact, for papers by Daniel S.W. Tan Breakdown of academic impact, for papers by Xiaoxiang Guan Breakdown of academic impact, for papers by Marzia Del Re Breakdown of academic impact, for papers by Dimitris Mavroudis Breakdown of academic impact, for papers by William Jacot Breakdown of academic impact, for papers by Yang Lü